FDA Orders Vision-Loss Warning on Ozempic, Zepbound and Other GLP-1 Drugs

The FDA ordered Novo Nordisk, Eli Lilly and AstraZeneca to warn of possible vision loss from NAION on all GLP-1 drug labels, matching Europe's earlier move.